Rapport Therapeutics rises on granting China rights for epilepsy drug

Rapport Therapeutics

09/03/2026 12:08

** Shares of drug developer Rapport Therapeutics RAPP.O gain 6.45% to $32.19 premarket

**  Company says it granted Tenacia exclusive Greater China rights to its experimental epilepsy drug RAP-219

**  RAPP'S RAP-219 aims to treat focal onset seizures — a type of epilepsy where seizures start in one area of the brain — and bipolar mania, co says

**  Co says Tenacia will run trials and commercialise the drug in China; Rapport to receive $20 mln upfront, up to $308 mln in milestones and royalties

**  RAP-219 showed reduced seizure episodes and was well tolerated in an early-stage study, co says

**  Companies plan to start global late-stage trials later this year - RAPP

** Shares up ~71% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))